Will rapid swabs vaccinate the counts of Giglio?
Giglio Group has signed an exclusive agreement for the distribution of rapid self-diagnosis tests from Covid-19. Facts, numbers and insights
Giglio Group will distribute, exclusively for Italy, the rapid self-diagnosis swabs from Covid-19, thanks to the agreement with Imago. The agreement represents an opportunity to consolidate the company's activity in the Star segment in the healthcare sector, a business line inaugurated during the 2020 lockdown.
Let's go step by step.
THE EXCLUSIVE AGREEMENT
Let's start with the facts. Giglio Group announced that it has signed an agreement with the company Imagro SPA for the distribution of the rapid self-diagnostic swabs "Boson Rapid SARS-Cov-2 Antigen Test", registered by the Ministry of Health on 9 April 2021, with the identification number 2089501 .
THE DISTRIBUTION
The tampons will be distributed in all Market Places, large, small and medium-sized enterprises, public bodies and trade associations, as well as being on sale on the e-commerce site www.gigliosalute.it.
THE RALLY IN THE BAG
The new business opportunity is liked by the market: the stock, outside the FTSE Mib, at 12 o'clock marked a plus 6.51% to 2.21 euros.
CONSOLIDATION OF THE HEALTHCARE SECTOR
The distribution agreement, in fact, will help Giglio Group to consolidate the company's activity in the healthcare sector, the business line born in 2020, in full lockdown, for the supply of masks and personal protective equipment to public bodies and regions. , Confindustria and Confcommercio.
“We are happy to include in our offer a product, authorized and registered by the Ministry of Health, unique of its kind, which can contribute quickly, easily and effectively to the containment of the pandemic. The demand for rapid self-diagnosis swabs is very high and will be increasingly so in the coming months, when it will be important to monitor the pandemic trend during the completion of the vaccination phase. We expect a rapid and wide distribution of the product ”, commented the president of the group Alessandro Giglio.
GIGLIO GROUP
The group, founded in 2003, and led by CEO Marco Riccardo Belloni, is a leader in Italy in the design, construction and management of e-commerce platforms with high added value for the worlds of Fashion, Design, Lifestyle and, more recently, Food. and Healthcare.
The company is headquartered in Milan and branches in New York, Shanghai, Rome, Lugano and Genoa
THE NUMBERS OF GIGLIO GROUP
In March 2021, the company recorded a turnover down by 28.9%, to 10.1 million euros, mainly due to the negative performance of the B2b division, "due to the cessation of marketing of Healthcare devices that characterized the first two quarters of 2020 ". Ebitda was 0.1 million euros, down compared to the first quarter of 2020, when the figure was 0.6 million.
Red also worsens: the loss is equal to 500 thousand euros and "is affected by 0.455 million in depreciation and compared to the result of -0.1 million of 03.31.2020 did not benefit from financial income of approximately 0.2 million accrued in quarter of 2020 ”, explains the company.
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/sanita/i-tamponi-rapidi-vaccineranno-i-conti-di-giglio/ on Tue, 25 May 2021 10:22:04 +0000.